CCM
HZNP

CAAS Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CAAS Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$732K – 1503
2020
Q4 		$732K Buy
+10,000
New +$743K 0.01% 647

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CAAS Capital Management's HZNP Position: Q1 2021 in Review

CAAS Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 10,000 shares — an estimated $732K sold.

CAAS Capital Management first reported a position in HZNP in Q4 2020 and held it in 1 quarter. The position peaked at $732K in Q4 2020. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

  • CAAS Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $732K.
  • CAAS Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $732K in Q4 2020.
  • 516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.